Abbott Laboratories

ABT

US0028241000

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 04:00:24 2024-06-10 pm EDT			5-day change	1st Jan Change
106.6 ^USD	-0.91%		+4.66%	-2.18%

02:33pm	Abbott Laboratories Says US FDA Approved 2 Over-The-Counter Continuous Glucose Monitoring Wearable Systems	MT
02:08pm	US FDA clears Abbott's continuous glucose monitors for over-the-counter use	RE

Abbott Laboratories Provides Earnings Guidance for the Year 2022

April 20, 2022 at 07:30 am EDT

Abbott Laboratories provided earnings guidance for the year 2022. The company projects full-year 2022 diluted earnings per share under GAAP of at least $3.35.

Latest news about Abbott Laboratories

Abbott Laboratories Says US FDA Approved 2 Over-The-Counter Continuous Glucose Monitoring Wearable Systems	08:33am	MT
US FDA clears Abbott's continuous glucose monitors for over-the-counter use	08:08am	RE
U.S. FDA set to reorganize its food division starting October	May. 30	RE
Redburn Adjusts Price Target on Abbott Laboratories to $113 From $115	May. 30	MT
Medtronic beats quarterly profit estimates on medical devices strength	May. 23	RE
Citigroup Adjusts Price Target on Abbott Laboratories to $119 From $128, Keeps Buy Rating	May. 22	MT
Abbott Laboratories Recalling HeartMate 3 Left Ventricular Assist System Implant Kit	May. 15	MT
Drugmaker Abbott India posts Q4 profit rise on higher sales	May. 09	RE
Abbott Laboratories Insider Sold Shares Worth $2,428,119, According to a Recent SEC Filing	May. 08	MT
Abbott Laboratories Announces Retirement of Robert E. Funck, Jr as Executive Vice President, Finance, Effective July 1, 2024	May. 01	CI
Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee	Apr. 29	MT
Dexcom's profit beats estimates on strong glucose monitor demand	Apr. 25	RE
Edwards Lifesciences first-quarter profit beats estimates on heart devices strength	Apr. 25	RE
Daiwa Securities Trims Abbott Laboratories Price Target to $125 From $126	Apr. 23	MT
Barclays Adjusts Abbott Laboratories' Price Target to $140 From $141, Maintains Overweight Rating	Apr. 22	MT
UBS Raises Abbott Laboratories Price Target to $143 from $136, Buy Rating Kept	Apr. 19	MT
Correction to Health Care Roundup Article	Apr. 18	DJ
RBC Lowers Price Target on Abbott Laboratories to $125 From $128, Keeps Outperform Rating	Apr. 18	MT
Raymond James Adjusts Abbott Laboratories' Price Target to $124 From $127, Keeps Outperform Rating	Apr. 18	MT
Health Care Down After Abbott Earnings -- Health Care Roundup	Apr. 17	DJ
Sector Update: Health Care Stocks Retreating Late Afternoon	Apr. 17	MT
S&P 500, Nasdaq dip as interest rate concerns, earnings weigh	Apr. 17	RE
Abbott Laboratories Raises Midpoint of 2024 Guidance After First-Quarter Beat	Apr. 17	MT
Top Stories at Midday: U.S. Bancorp, Abbott, Citizens Financial, First Horizon, Prologis, ASML, Travelers Report Earnings; Tesla Asks Shareholders Vote on Musk's Compensation; Eli Lilly Sleep Apnea Drug Trials Hit Primary Endpoints	Apr. 17	MT
Wall St slips as dour earnings, chip stocks weigh	Apr. 17	RE

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-17 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Abbott Laboratories

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

107.6 USD

Average target price

125.4 USD

Spread / Average Target

+16.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-2.18%	187B
MEDTRONIC PLC	+1.00%	110B
BECTON, DICKINSON AND COMPANY	-1.83%	69.54B
CENCORA, INC.	+14.35%	46.37B
DEXCOM, INC.	-6.03%	46.05B
HOYA CORPORATION	+7.97%	42.54B
METTLER-TOLEDO INTERNATIONAL, INC.	+18.54%	30.72B
TERUMO CORPORATION	+17.70%	25.62B
ZIMMER BIOMET HOLDINGS, INC.	-7.29%	23.32B
WEST PHARMACEUTICAL SERVICES, INC.	-9.31%	22.92B

Other Medical Equipment, Supplies & Distribution